Identification of immune subtypes of uterine corpus endometrial adenocarcinoma based on tumour microenvironment

Uterine corpus endometrial adenocarcinoma is the prevalent gynaecological malig-nancy. The related morbidity and mortality are high despite the progress made in treatments. Therefore, efficient prognostic indicators and reliable predictive factors for the treatments are vital. In this study, the transcriptome and clinical data of endometrial adenocarcinoma samples were screened and downloaded from The Cancer Genome Atlas Program (TCGA) database. The relation between immune cell types and clinicopathological grade of endometrial adenocarcinoma was explored. The endometrial adenocarcinoma samples were divided into six immune subtypes based on immune microenvironment scores. The differential genes in immune subtypes were classified according to the score, and correlation enrichment analysis was made to explore the immune pathways related to prognosis and survival. They were divided into high and low risk groups according to the median risk score in order to explore the survival outcomes of the various immune scores. Finally, the relationship between tumour mutation burden, immune subtypes, and prognosis was discussed. Herein, the endometrial adenocarcinoma is classified based on immune microenvironment which demonstrates good predictive potential of immune-based classification strategy. The predicted outcomes are described for the patients at high risk of endometrial adenocarcinoma to improve the treatment strategies. Immune risk score can be used as an independent risk factor for overall survival of endometrial adenocarcinoma patients. This immune-based classification system can prognose endometrial adenocarcinoma patients at high risk.

Uterine corpus endometrial adenocarcinoma; Tumour microenvironment; Immune cell infiltration

[1] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015; 136: E359–E386.

[2] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022; 399: 1412–1428.

[3] Cai Y, Wang B, Xu W, Liu K, Gao Y, Guo C, et al. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine. Current Medicinal Chemistry. 2021; 28: 8755–8781.

[4] Jiang X, Tang H, Chen T. Epidemiology of gynecologic cancers in China. Journal of Gynecologic Oncology. 2018; 29: e7.

[5] Yu Q, Wang J, Li T, Xu X, Guo X, Ding S, et al. RON mediates tumor-promoting effects in endometrial adenocarcinoma. BioMed Research International. 2021; 2021: 2282916.

[6] Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. The Lancet. Global health. 2018; 6: e555–e567.

[7] Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacology & Therapeutics. 2021; 221: 107753.

[8] Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Molecular Cancer. 2018; 17: 108.

[9] Jiang Y, Wang C, Zhou S. Targeting tumor microenvironment in ovarian cancer: premise and promise. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer. 2020; 1873: 188361.

[10] Degos C, Heinemann M, Barrou J, Boucherit N, Lambaudie E, Savina A, et al. Endometrial tumor microenvironment alters human NK cell recruitment, and resident NK cell phenotype and function. Frontiers in Immunology. 2019; 10: 877.

[11] Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nature Biotechnology. 2019; 37: 773–782.

[12] Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nature Communications. 2013; 4: 2612.

[13] Chang JT, Nevins JR. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics. 2006; 22: 2926–2933.

[14] The Gene Ontology Consortium. Expansion of the gene ontology knowledgebase and resources. Nucleic Acids Research. 2017; 45: D331–D338.

[15] Kanehisa M. Enzyme annotation and metabolic reconstruction using KEGG. Methods in Molecular Biology. 2017; 1611: 135–145.

[16] Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine. 2017; 9: 34.

[17] Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Research. 2018; 28: 1747–1756.

[18] Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma. Cancer Medicine. 2018; 7: 5632–5642.

[19] Liu J, Geng R, Yang S, Shao F, Zhong Z, Yang M, et al. Development and clinical validation of novel 8-gene prognostic signature associated with the proportion of regulatory T cells by weighted gene co-expression network analysis in uterine corpus endometrial carcinoma. Frontiers in Immunology. 2021; 12: 788431.

[20] Zhang L, Wan Y, Zhang Z, Jiang Y, Gu Z, Ma X, et al. IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression. Theranostics. 2021; 11: 1100–1114.

[21] Zhong Q, Fan J, Chu H, Pang M, Li J, Fan Y, et al. Integrative analysis of genomic and epigenetic regulation of endometrial cancer. Aging. 2020; 12: 9260–9274.

[22] Zheng J, Zhang YW, Pan ZF. Dysregulation of MAD2L1/CAMK2A/PTTG1 gene cluster maintains the stemness characteristics of uterine corpus endometrial carcinoma. Acta Academiae Medicinae Sinicae. 2021; 43: 685–695. (In Chinese)

[23] Sertic S, Quadri R, Lazzaro F, Muzi-Falconi M. EXO1: a tightly regulated nuclease. DNA Repair. 2020; 93: 102929.

[24] Wang S, Lee K, Gray S, Zhang Y, Tang C, Morrish RB, et al. Role of EXO1 nuclease activity in genome maintenance, the immune response and tumor suppression in Exo1D173A mice. Nucleic Acids Research. 2022; 50: 8093–8106.

[25] Yan Y, Liu C, Zhang J, Li W, Yin X, Dong L, et al. SMC4 knockdown inhibits malignant biological behaviors of endometrial cancer cells by regulation of FoxO1 activity. Archives of Biochemistry and Biophysics. 2021; 712: 109026.

[26] Qiu X, Gao Z, Shao J, Li H. NCAPH is upregulated in endometrial cancer and associated with poor clinicopathologic characteristics. Annals of Human Genetics. 2020; 84: 437–446.

[27] He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on Immunogenomic profiling. Journal of Experimental & Clinical Cancer Research. 2018; 37: 327.

[28] Bell DW, Ellenson LH. Molecular genetics of endometrial carcinoma. Annual Review of Pathology. 2019; 14: 339–367.

[29] Russo M, Newell JM, Budurlean L, Houser KR, Sheldon K, Kesterson J, et al. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer. 2020; 126: 2775–2783.

[30] Ono K, Kasajima R, Katayama K, Miyagi Y, Yokose T. Clinicopatho-logical and molecular characteristics of endometrial neuroendocrine carcinomas reveal preexisting endometrial carcinoma origin. Pathology International. 2021; 71: 491–499.

[31] Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67–73.

[32] Prvanović M, Nedeljković M, Tanić N, Tomić T, Terzić T, Milovanović Z, et al. Role of PTEN, PI3K, and mTOR in triple-negative breast cancer. Life. 2021; 11: 1247.

[33] Efsun Antmen S, Canacankatan N, Gürses İ, Aytan H, Erden Ertürk S. Relevance of lipogenesis and AMPK/Akt/mTOR signaling pathway in endometrial cancer. European Review for Medical and Pharmacological Sciences. 2021; 25: 687–695.